Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain
Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the...
Saved in:
| Published in | mSphere Vol. 10; no. 7; p. e0018425 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
07.07.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. |
|---|---|
| AbstractList | Tick-borne encephalitis virus (TBEV) belongs to the genus
and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an
BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.
Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both
and
models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. ABSTRACT Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.IMPORTANCETick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. ABSTRACTTick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.IMPORTANCETick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain. Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis.IMPORTANCETick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain.IMPORTANCETick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific antiviral treatment is available for tick-borne encephalitis caused by virus multiplication in the brain. The delivery of drugs to the brain via peripheral administration is often obstructed by the blood-brain barrier. To develop targeted antiviral therapies for brain infections, we engineered recombinant antibodies capable of crossing the blood-brain barrier via brain-targeted ligands. These antibodies exhibited permeability across the blood-brain barrier in both in vitro and in vivo models and notably effectively neutralized the virus within the brain following peripheral administration. This study is the first to highlight the therapeutic potential of brain-targeted recombinant antibodies after viral entry into the brain, offering a promising pathway for the development of effective antiviral treatments for tick-borne encephalitis. |
| Author | Yoshii, Kentaro Fukano, Sayo Kobayashi, Shintaro Nio-Kobayashi, Junko Hirano, Minato Fukuta, Mizuki Maekawa, Naoya Kariwa, Hiroaki Kawakami, Shigeru Okamoto, Shunsuke Konnai, Satoru |
| Author_xml | – sequence: 1 givenname: Mizuki orcidid: 0009-0009-3057-755X surname: Fukuta fullname: Fukuta, Mizuki – sequence: 2 givenname: Sayo surname: Fukano fullname: Fukano, Sayo – sequence: 3 givenname: Naoya surname: Maekawa fullname: Maekawa, Naoya – sequence: 4 givenname: Shintaro surname: Kobayashi fullname: Kobayashi, Shintaro – sequence: 5 givenname: Shunsuke surname: Okamoto fullname: Okamoto, Shunsuke – sequence: 6 givenname: Minato surname: Hirano fullname: Hirano, Minato – sequence: 7 givenname: Junko surname: Nio-Kobayashi fullname: Nio-Kobayashi, Junko – sequence: 8 givenname: Hiroaki surname: Kariwa fullname: Kariwa, Hiroaki – sequence: 9 givenname: Shigeru surname: Kawakami fullname: Kawakami, Shigeru – sequence: 10 givenname: Satoru orcidid: 0000-0002-3230-7109 surname: Konnai fullname: Konnai, Satoru – sequence: 11 givenname: Kentaro orcidid: 0000-0002-1104-0898 surname: Yoshii fullname: Yoshii, Kentaro |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40622136$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kktv1DAURiNUREvpnhWKxIZNil-xMyuESguVKrGBteXH9YyHxA52MlL59XgmQ2mRWNnyd3Tke_W9rE5CDFBVrzG6xJh074c8biDBJUK4Yw1pn1VnhIpV0yJGTh7dT6uLnLeoYJxwLviL6pQhTgim_KyaP8EO-jgOEKY6ulr3MdpGJ-VDrVVKHlIzQoApqcmHda3C5HW0HnLtYqoDzCXp_a99Nnnzo9ExBaghGBg3JZh8rnc-zbkuwmkD9UH9qnruVJ_h4nieV99vrr9dfWnuvn6-vfp416iWdFMDiOmOdEBca7kSorOKdRoZzix3TLAWBHNaWOCaM6qZA8XbFQOLOabQIXpe3S5eG9VWjskPKt3LqLw8PMS0liqVb_cgHYVVyxkXLRiGCOqUAWc0EMsUNUQV14fFNc56AGvKwsrkT6RPk-A3ch13EhOKOBZtMbw7GlL8OUOe5OCzgb5XAeKcJSVEcNpxsSro23_QbZxTKLsqFGViJRZhs1AqD-QvgZHcF0QeCyIPBZFkz795PMLD3__UoQBoAUyKOSdwD8h_nb8BsZzMxQ |
| Cites_doi | 10.1016/j.ttbdis.2016.03.002 10.1016/j.antiviral.2019.01.014 10.1016/s0166-3542(02)00206-1 10.1016/j.chom.2018.03.001 10.1080/13550280590900427 10.1186/2045-8118-10-16 10.1016/j.virusres.2005.04.007 10.1371/journal.pone.0020472 10.1080/10717544.2023.2173333 10.2174/0929866522666151026122752 10.1016/j.virol.2009.04.026 10.3390/brainsci12081020 10.1038/s41467-018-02882-0 10.1111/pbi.12719 10.1093/jnen/64.6.506 10.1086/515195 10.1002/rmv.2470 10.1007/s10354-012-0105-0 10.1016/S0264-410X(98)00360-0 10.3390/microorganisms11071634 10.1016/j.ijmm.2006.01.023 10.1006/viro.1996.0261 10.1016/S0264-410X(02)00811-3 10.1111/bph.15802 10.1001/jama.2023.13239 10.1016/j.ijpharm.2018.03.028 10.1099/jgv.0.001400 10.1016/j.biomaterials.2019.119491 10.1146/annurev-pharmtox-010814-124852 10.1099/vir.0.19668-0 10.1126/sciadv.abm8011 10.1016/j.addr.2006.01.026 10.1056/NEJMc2301380 10.3389/fimmu.2024.1399438 10.7150/thno.21254 10.1039/d1ra08131d 10.1128/AAC.00807-15 10.1186/s12974-019-1596-z 10.1016/j.biomaterials.2009.02.051 10.1016/j.brainres.2020.146738 10.1016/j.antiviral.2011.10.023 10.1016/j.virusres.2022.198914 10.1039/c6cs00076b 10.1016/j.vaccine.2020.04.051 10.1084/jem.20210236 10.1093/clinchem/45.7.942 10.1016/j.tmaid.2010.06.004 10.1007/s11095-020-02865-1 10.1002/jcp.28490 10.1016/s0022-1759(99)00184-2 10.1038/nature05901 10.1186/1743-422X-11-10 10.1177/2211068214561025 10.1099/vir.0.011437-0 10.1080/02648725.2013.801235 10.1016/j.addr.2011.11.010 10.3892/mmr.2015.3980 10.1016/j.vaccine.2007.08.024 10.2174/138920112803341851 10.1111/j.1468-1331.2010.03278.x 10.1016/j.vaccine.2014.05.012 10.1128/JVI.01028-17 10.1186/s12974-020-01943-w 10.1093/brain/122.11.2067 10.1016/j.neuron.2013.10.061 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Fukuta et al. Copyright © 2025 Fukuta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2025 Fukuta et al. 2025 Fukuta et al. |
| Copyright_xml | – notice: Copyright © 2025 Fukuta et al. – notice: Copyright © 2025 Fukuta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2025 Fukuta et al. 2025 Fukuta et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1128/msphere.00184-25 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2379-5042 |
| Editor | Pasetti, Marcela F. |
| Editor_xml | – sequence: 1 givenname: Marcela F. surname: Pasetti fullname: Pasetti, Marcela F. |
| ExternalDocumentID | oai_doaj_org_article_f3e9564675ec40208acefcbe2d4a3c2a PMC12306175 msphere00184-25 40622136 10_1128_msphere_00184_25 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Japan Society for the Promotion of Science grantid: 23KJ1760 – fundername: Japan Society for the Promotion of Science grantid: 21K20761,22K15012 – fundername: Japan Society for the Promotion of Science grantid: 20H03136,21KK0123,21K19191,23K27079 – fundername: Japan Agency for Medical Research and Development grantid: JP24fm0208101,JP23fk0108614,JP23wm0325059 – fundername: Japan Society for the Promotion of Science grantid: 20H03136,21KK0123,21K19191,23K27079 funderid: http://dx.doi.org/10.13039/501100001691 – fundername: Japan Agency for Medical Research and Development grantid: JP24fm0208101,JP23fk0108614,JP23wm0325059 funderid: http://dx.doi.org/10.13039/100009619 – fundername: Japan Society for the Promotion of Science grantid: 21K20761,22K15012 funderid: http://dx.doi.org/10.13039/501100001691 – fundername: Japan Society for the Promotion of Science grantid: 23KJ1760 funderid: http://dx.doi.org/10.13039/501100001691 – fundername: ; grantid: 23KJ1760 – fundername: ; grantid: JP24fm0208101,JP23fk0108614,JP23wm0325059 – fundername: ; grantid: 21K20761,22K15012 – fundername: ; grantid: 20H03136,21KK0123,21K19191,23K27079 |
| GroupedDBID | 0R~ 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAGFI AAUOK AAYXX ABUWG ADBBV AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK EBS FRP FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE KQ8 LK8 M7P M~E O9- OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC R9- RHI RPM RSF UKHRP CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. M48 PKEHL PQEST PQUKI PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-a528t-e04b828e2f5d6a778da48b0c64d6f4745e74fb7de6b643b4fea6594ed1613e803 |
| IEDL.DBID | DOA |
| ISSN | 2379-5042 |
| IngestDate | Wed Aug 27 01:32:18 EDT 2025 Thu Aug 21 18:33:44 EDT 2025 Fri Jul 11 16:57:03 EDT 2025 Sat Aug 23 14:34:10 EDT 2025 Tue Jul 29 18:27:49 EDT 2025 Fri Aug 01 03:41:23 EDT 2025 Thu Jul 31 00:05:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | blood-brain barrier rabies virus glycoprotein recombinant antibody tick-borne encephalitis virus |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a528t-e04b828e2f5d6a778da48b0c64d6f4745e74fb7de6b643b4fea6594ed1613e803 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 The authors declare no conflict of interest. |
| ORCID | 0000-0002-1104-0898 0009-0009-3057-755X 0000-0002-3230-7109 |
| OpenAccessLink | https://doaj.org/article/f3e9564675ec40208acefcbe2d4a3c2a |
| PMID | 40622136 |
| PQID | 3234797175 |
| PQPubID | 2045592 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f3e9564675ec40208acefcbe2d4a3c2a pubmedcentral_primary_oai_pubmedcentral_nih_gov_12306175 proquest_miscellaneous_3227638679 proquest_journals_3234797175 asm2_journals_10_1128_msphere_00184_25 pubmed_primary_40622136 crossref_primary_10_1128_msphere_00184_25 |
| PublicationCentury | 2000 |
| PublicationDate | 20250707 |
| PublicationDateYYYYMMDD | 2025-07-07 |
| PublicationDate_xml | – month: 7 year: 2025 text: 20250707 day: 7 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC – name: Washington |
| PublicationTitle | mSphere |
| PublicationTitleAbbrev | mSphere |
| PublicationTitleAlternate | mSphere |
| PublicationYear | 2025 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_50_2 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_58_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_56_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_61_2 e_1_3_3_5_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_67_2 e_1_3_3_44_2 e_1_3_3_65_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_63_2 e_1_3_3_51_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_59_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_57_2 e_1_3_3_32_2 e_1_3_3_55_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_62_2 e_1_3_3_60_2 Niedrig M (e_1_3_3_26_2) 1994; 38 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_45_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_66_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_64_2 Niedrig, M, Klockmann, U, Lang, W, Roeder, J, Burk, S, Modrow, S, Pauli, G (B25) 1994; 38 Chiffi, G, Grandgirard, D, Leib, SL, Chrdle, A, Růžek, D (B2) 2023; 33 Liu, Y, Huang, R, Han, L, Ke, W, Shao, K, Ye, L, Lou, J, Jiang, C (B45) 2009; 30 Presta, LG (B50) 2006; 58 Mandl, CW (B55) 2005; 111 Lu, W (B39) 2012; 13 Kricka, LJ (B49) 1999; 45 Czupryna, P, Moniuszko, A, Pancewicz, SA, Grygorczuk, S, Kondrusik, M, Zajkowska, J (B62) 2011; 18 van Dyck, CH, Sabbagh, M, Cohen, S (B52) 2023; 388 Takahashi, Y, Kobayashi, S, Ishizuka, M, Hirano, M, Muto, M, Nishiyama, S, Kariwa, H, Yoshii, K (B6) 2020; 101 Ruzek, D, Avšič Županc, T, Borde, J, Chrdle, A, Eyer, L, Karganova, G, Kholodilov, I, Knap, N, Kozlovskaya, L, Matveev, A, Miller, AD, Osolodkin, DI, Överby, AK, Tikunova, N, Tkachev, S, Zajkowska, J (B46) 2019; 164 Mansfield, KL, Johnson, N, Phipps, LP, Stephenson, JR, Fooks, AR, Solomon, T (B13) 2009; 90 Lafon, M (B22) 2005; 11 Weksler, B, Romero, IA, Couraud, P-O (B32) 2013; 10 Shi, Z, Wei, J, Deng, X, Li, S, Qiu, Y, Shao, D, Li, B, Zhang, K, Xue, F, Wang, X, Ma, Z (B59) 2014; 11 Růžek, D, Dobler, G, Donoso Mantke, O (B5) 2010; 8 Kaiser, R (B4) 2012; 162 Pokorna Formanova, P, Palus, M, Salat, J, Hönig, V, Stefanik, M, Svoboda, P, Ruzek, D (B33) 2019; 16 Safdari, Y, Farajnia, S, Asgharzadeh, M, Khalili, M (B54) 2013; 29 Achazi, K, Patel, P, Paliwal, R, Radonić, A, Niedrig, M, Donoso-Mantke, O (B64) 2012; 93 Kumar, P, Wu, H, McBride, JL, Jung, K-E, Hee Kim, M, Davidson, BL, Kyung Lee, S, Shankar, P, Manjunath, N (B23) 2007; 448 Kato, N, Yamada, S, Suzuki, R, Iida, Y, Matsumoto, M, Fumoto, S, Arima, H, Mukai, H, Kawakami, S (B28) 2023; 30 Füzik, T, Formanová, P, Růžek, D, Yoshii, K, Niedrig, M, Plevka, P (B31) 2018; 9 Inagaki, E, Sakai, M, Hirano, M, Muto, M, Kobayashi, S, Kariwa, H, Yoshii, K (B30) 2016; 7 Chen, Y, Liu, L (B19) 2012; 64 Lajoie, JM, Shusta, EV (B20) 2015; 55 Agudelo, M, Palus, M, Keeffe, JR, Bianchini, F, Svoboda, P, Salát, J, Peace, A, Gazumyan, A, Cipolla, M, Kapoor, T, Guidetti, F, Yao, K-H, Elsterová, J, Teislerová, D, Chrdle, A, Hönig, V, Oliveira, T, West, AP, Lee, YE, Rice, CM, MacDonald, MR, Bjorkman, PJ, Růžek, D, Robbiani, DF, Nussenzweig, MC (B27) 2021; 218 Phoolcharoen, W, Prehaud, C, van Dolleweerd, CJ, Both, L, da Costa, A, Lafon, M, Ma, J-C (B36) 2017; 15 Hayasaka, D, Nagata, N, Fujii, Y, Hasegawa, H, Sata, T, Suzuki, R, Gould, EA, Takashima, I, Koike, S (B56) 2009; 390 Sims, JR, Zimmer, JA, Evans, CD, Lu, M, Ardayfio, P, Sparks, J, Wessels, AM, Shcherbinin, S, Wang, H, Monkul Nery, ES, Collins, EC, Solomon, P, Salloway, S, Apostolova, LG, Hansson, O, Ritchie, C, Brooks, DA, Mintun, M, Skovronsky, DM (B51) 2023; 330 Hua, H, Zhang, X, Mu, H, Meng, Q, Jiang, Y, Wang, Y, Lu, X, Wang, A, Liu, S, Zhang, Y, Wan, Z, Sun, K (B44) 2018; 543 Baykov, IK, Matveev, AL, Stronin, OV, Ryzhikov, AB, Matveev, LE, Kasakin, MF, Richter, VA, Tikunova, NV (B16) 2014; 32 Dong, X (B18) 2018; 8 Gordon, GL, Raybould, MIJ, Wong, A, Deane, CM (B53) 2024; 15 Cheng, Y, Li, Z, Xi, H, Gu, T, Yuan, R, Chen, X, Jiang, C, Kong, W, Wu, Y (B37) 2016; 23 Volok, VP, Gmyl, LV, Belyaletdinova, IK, Karganova, GG, Dekonenko, EP (B63) 2022; 12 Oller-Salvia, B, Sánchez-Navarro, M, Giralt, E, Teixidó, M (B21) 2016; 45 Niewoehner, J, Bohrmann, B, Collin, L, Urich, E, Sade, H, Maier, P, Rueger, P, Stracke, JO, Lau, W, Tissot, AC, Loetscher, H, Ghosh, A, Freskgård, P-O (B34) 2014; 81 Pustijanac, E, Buršić, M, Talapko, J, Škrlec, I, Meštrović, T, Lišnjić, D (B1) 2023; 11 Kaiser, R (B12) 1999; 122 Wang, Z, Raifu, M, Howard, M, Smith, L, Hansen, D, Goldsby, R, Ratner, D (B26) 2000; 233 Haglund, M, Günther, G (B14) 2003; 21 Jiang, X, Zhai, J, Song, D, Qu, Q, Li, M, Xing, L, Miao, S (B38) 2015; 12 Eyer, L, Valdés, JJ, Gil, VA, Nencka, R, Hřebabecký, H, Šála, M, Salát, J, Černý, J, Palus, M, De Clercq, E, Růžek, D (B65) 2015; 59 Srinivasan, B, Kolli, AR, Esch, MB, Abaci, HE, Shuler, ML, Hickman, JJ (B29) 2015; 20 Xie, J, Shen, Z, Anraku, Y, Kataoka, K, Chen, X (B40) 2019; 224 Gritsun, TS, Lashkevich, VA, Gould, EA (B11) 2003; 57 Matveev, A, Matveev, L, Stronin, O, Baykov, I, Emeljanova, L, Khlusevich, Y, Tikunova, N (B17) 2020; 38 Eyer, L, Kondo, H, Zouharova, D, Hirano, M, Valdés, JJ, Muto, M, Kastl, T, Kobayashi, S, Haviernik, J, Igarashi, M, Kariwa, H, Vaculovicova, M, Cerny, J, Kizek, R, Kröger, A, Lienenklaus, S, Dejmek, M, Nencka, R, Palus, M, Salat, J, De Clercq, E, Yoshii, K, Ruzek, D (B61) 2017; 91 Dos Santos Rodrigues, B, Arora, S, Kanekiyo, T, Singh, J (B43) 2020; 1734 Anami, Y, Xiong, W, Yamaguchi, A, Yamazaki, CM, Zhang, N, An, Z, Tsuchikama, K (B35) 2022; 12 Heinz, FX, Holzmann, H, Essl, A, Kundi, M (B3) 2007; 25 Dumpis, U, Crook, D, Oksi, J (B10) 1999; 28 Pan, Y, Nicolazzo, JA (B48) 2022; 179 Beloor, J, Maes, N, Ullah, I, Uchil, P, Jackson, A, Fikrig, E, Lee, SK, Kumar, P (B58) 2018; 23 Yarian, F, Alibakhshi, A, Eyvazi, S, Arezumand, R, Ahangarzadeh, S (B66) 2019; 234 Labuda, M, Austyn, JM, Zuffova, E, Kozuch, O, Fuchsberger, N, Lysy, J, Nuttall, PA (B9) 1996; 219 Lindqvist, R, Rosendal, E, Weber, E, Asghar, N, Schreier, S, Lenman, A, Johansson, M, Dobler, G, Bestehorn, M, Kröger, A, Överby, AK (B8) 2020; 17 Hayasaka, D, Gritsun, TS, Yoshii, K, Ueki, T, Goto, A, Mizutani, T, Kariwa, H, Iwasaki, T, Gould, EA, Takashima, I (B24) 2004; 85 Růžek, D, Salát, J, Singh, SK, Kopecký, J (B47) 2011; 6 Poponnikova, TV (B15) 2006; 296 Gelpi, E, Preusser, M, Garzuly, F, Holzmann, H, Heinz, FX, Budka, H (B57) 2005; 64 Pinheiro, RGR, Granja, A, Loureiro, JA, Pereira, MC, Pinheiro, M, Neves, AR, Reis, S (B41) 2020; 37 Tsujino, D, Yoshii, K, Kajiyama, M, Takahashi, Y, Maekawa, N, Kariwa, H, Kobayashi, S (B7) 2022; 321 Zou, Y, Sun, X, Yang, Q, Zheng, M, Shimoni, O, Ruan, W, Wang, Y, Zhang, D, Yin, J, Huang, X, Tao, W, Park, JB, Liang, XJ, Leong, KW, Shi, B (B42) 2022; 8 Chiba, N, Osada, M, Komoro, K, Mizutani, T, Kariwa, H, Takashima, I (B60) 1999; 17 |
| References_xml | – ident: e_1_3_3_31_2 doi: 10.1016/j.ttbdis.2016.03.002 – ident: e_1_3_3_47_2 doi: 10.1016/j.antiviral.2019.01.014 – ident: e_1_3_3_12_2 doi: 10.1016/s0166-3542(02)00206-1 – ident: e_1_3_3_59_2 doi: 10.1016/j.chom.2018.03.001 – ident: e_1_3_3_23_2 doi: 10.1080/13550280590900427 – ident: e_1_3_3_33_2 doi: 10.1186/2045-8118-10-16 – ident: e_1_3_3_56_2 doi: 10.1016/j.virusres.2005.04.007 – ident: e_1_3_3_48_2 doi: 10.1371/journal.pone.0020472 – ident: e_1_3_3_29_2 doi: 10.1080/10717544.2023.2173333 – ident: e_1_3_3_38_2 doi: 10.2174/0929866522666151026122752 – ident: e_1_3_3_57_2 doi: 10.1016/j.virol.2009.04.026 – ident: e_1_3_3_64_2 doi: 10.3390/brainsci12081020 – ident: e_1_3_3_32_2 doi: 10.1038/s41467-018-02882-0 – ident: e_1_3_3_37_2 doi: 10.1111/pbi.12719 – ident: e_1_3_3_58_2 doi: 10.1093/jnen/64.6.506 – ident: e_1_3_3_11_2 doi: 10.1086/515195 – ident: e_1_3_3_3_2 doi: 10.1002/rmv.2470 – ident: e_1_3_3_5_2 doi: 10.1007/s10354-012-0105-0 – ident: e_1_3_3_61_2 doi: 10.1016/S0264-410X(98)00360-0 – ident: e_1_3_3_2_2 doi: 10.3390/microorganisms11071634 – ident: e_1_3_3_16_2 doi: 10.1016/j.ijmm.2006.01.023 – volume: 38 start-page: 141 year: 1994 ident: e_1_3_3_26_2 article-title: Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo publication-title: Acta Virol – ident: e_1_3_3_10_2 doi: 10.1006/viro.1996.0261 – ident: e_1_3_3_15_2 doi: 10.1016/S0264-410X(02)00811-3 – ident: e_1_3_3_49_2 doi: 10.1111/bph.15802 – ident: e_1_3_3_52_2 doi: 10.1001/jama.2023.13239 – ident: e_1_3_3_45_2 doi: 10.1016/j.ijpharm.2018.03.028 – ident: e_1_3_3_7_2 doi: 10.1099/jgv.0.001400 – ident: e_1_3_3_41_2 doi: 10.1016/j.biomaterials.2019.119491 – ident: e_1_3_3_21_2 doi: 10.1146/annurev-pharmtox-010814-124852 – ident: e_1_3_3_25_2 doi: 10.1099/vir.0.19668-0 – ident: e_1_3_3_43_2 doi: 10.1126/sciadv.abm8011 – ident: e_1_3_3_51_2 doi: 10.1016/j.addr.2006.01.026 – ident: e_1_3_3_53_2 doi: 10.1056/NEJMc2301380 – ident: e_1_3_3_54_2 doi: 10.3389/fimmu.2024.1399438 – ident: e_1_3_3_19_2 doi: 10.7150/thno.21254 – ident: e_1_3_3_36_2 doi: 10.1039/d1ra08131d – ident: e_1_3_3_66_2 doi: 10.1128/AAC.00807-15 – ident: e_1_3_3_34_2 doi: 10.1186/s12974-019-1596-z – ident: e_1_3_3_46_2 doi: 10.1016/j.biomaterials.2009.02.051 – ident: e_1_3_3_44_2 doi: 10.1016/j.brainres.2020.146738 – ident: e_1_3_3_65_2 doi: 10.1016/j.antiviral.2011.10.023 – ident: e_1_3_3_8_2 doi: 10.1016/j.virusres.2022.198914 – ident: e_1_3_3_22_2 doi: 10.1039/c6cs00076b – ident: e_1_3_3_18_2 doi: 10.1016/j.vaccine.2020.04.051 – ident: e_1_3_3_28_2 doi: 10.1084/jem.20210236 – ident: e_1_3_3_50_2 doi: 10.1093/clinchem/45.7.942 – ident: e_1_3_3_6_2 doi: 10.1016/j.tmaid.2010.06.004 – ident: e_1_3_3_42_2 doi: 10.1007/s11095-020-02865-1 – ident: e_1_3_3_67_2 doi: 10.1002/jcp.28490 – ident: e_1_3_3_27_2 doi: 10.1016/s0022-1759(99)00184-2 – ident: e_1_3_3_24_2 doi: 10.1038/nature05901 – ident: e_1_3_3_60_2 doi: 10.1186/1743-422X-11-10 – ident: e_1_3_3_30_2 doi: 10.1177/2211068214561025 – ident: e_1_3_3_14_2 doi: 10.1099/vir.0.011437-0 – ident: e_1_3_3_55_2 doi: 10.1080/02648725.2013.801235 – ident: e_1_3_3_20_2 doi: 10.1016/j.addr.2011.11.010 – ident: e_1_3_3_39_2 doi: 10.3892/mmr.2015.3980 – ident: e_1_3_3_4_2 doi: 10.1016/j.vaccine.2007.08.024 – ident: e_1_3_3_40_2 doi: 10.2174/138920112803341851 – ident: e_1_3_3_63_2 doi: 10.1111/j.1468-1331.2010.03278.x – ident: e_1_3_3_17_2 doi: 10.1016/j.vaccine.2014.05.012 – ident: e_1_3_3_62_2 doi: 10.1128/JVI.01028-17 – ident: e_1_3_3_9_2 doi: 10.1186/s12974-020-01943-w – ident: e_1_3_3_13_2 doi: 10.1093/brain/122.11.2067 – ident: e_1_3_3_35_2 doi: 10.1016/j.neuron.2013.10.061 – volume: 6 year: 2011 ident: B47 article-title: Breakdown of the blood-brain barrier during tick-borne encephalitis in mice is not dependent on CD8+ T-cells publication-title: PLoS One doi: 10.1371/journal.pone.0020472 – volume: 15 year: 2024 ident: B53 article-title: Prospects for the computational humanization of antibodies and nanobodies publication-title: Front Immunol doi: 10.3389/fimmu.2024.1399438 – volume: 13 start-page: 2340 year: 2012 end-page: 2348 ident: B39 article-title: Adsorptive-mediated brain delivery systems publication-title: Curr Pharm Biotechnol doi: 10.2174/138920112803341851 – volume: 11 start-page: 82 year: 2005 end-page: 87 ident: B22 article-title: Rabies virus receptors publication-title: J Neurovirol doi: 10.1080/13550280590900427 – volume: 11 year: 2014 ident: B59 article-title: Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model publication-title: Virol J doi: 10.1186/1743-422X-11-10 – volume: 8 year: 2022 ident: B42 article-title: Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy publication-title: Sci Adv doi: 10.1126/sciadv.abm8011 – volume: 164 start-page: 23 year: 2019 end-page: 51 ident: B46 article-title: Tick-borne encephalitis in Europe and Russia: review of pathogenesis, clinical features, therapy, and vaccines publication-title: Antiviral Res doi: 10.1016/j.antiviral.2019.01.014 – volume: 10 year: 2013 ident: B32 article-title: The hCMEC/D3 cell line as a model of the human blood brain barrier publication-title: Fluids Barriers CNS doi: 10.1186/2045-8118-10-16 – volume: 33 year: 2023 ident: B2 article-title: Tick-borne encephalitis: a comprehensive review of the epidemiology, virology, and clinical picture publication-title: Rev Med Virol doi: 10.1002/rmv.2470 – volume: 9 year: 2018 ident: B31 article-title: Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody publication-title: Nat Commun doi: 10.1038/s41467-018-02882-0 – volume: 81 start-page: 49 year: 2014 end-page: 60 ident: B34 article-title: Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle publication-title: Neuron doi: 10.1016/j.neuron.2013.10.061 – volume: 91 year: 2017 ident: B61 article-title: Escape of tick-borne flavivirus from 2'-C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness publication-title: J Virol doi: 10.1128/JVI.01028-17 – volume: 18 start-page: 673 year: 2011 end-page: 679 ident: B62 article-title: Tick-borne encephalitis in Poland in years 1993–2008 – epidemiology and clinical presentation. A retrospective study of 687 patients publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.03278.x – volume: 11 year: 2023 ident: B1 article-title: Tick-borne encephalitis virus: a comprehensive review of transmission, pathogenesis, epidemiology, clinical manifestations, diagnosis, and prevention publication-title: Microorganisms doi: 10.3390/microorganisms11071634 – volume: 59 start-page: 5483 year: 2015 end-page: 5493 ident: B65 article-title: Nucleoside inhibitors of tick-borne encephalitis virus publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00807-15 – volume: 12 start-page: 3359 year: 2022 end-page: 3364 ident: B35 article-title: Homogeneous antibody-angiopep 2 conjugates for effective brain targeting publication-title: RSC Adv doi: 10.1039/d1ra08131d – volume: 101 start-page: 497 year: 2020 end-page: 509 ident: B6 article-title: Characterization of tick-borne encephalitis virus isolated from a tick in central Hokkaido in 2017 publication-title: J Gen Virol doi: 10.1099/jgv.0.001400 – volume: 28 start-page: 882 year: 1999 end-page: 890 ident: B10 article-title: Tick-borne encephalitis publication-title: Clin Infect Dis doi: 10.1086/515195 – volume: 7 start-page: 723 year: 2016 end-page: 729 ident: B30 article-title: Development of a serodiagnostic multi-species ELISA against tick-borne encephalitis virus using subviral particles publication-title: Ticks Tick Borne Dis doi: 10.1016/j.ttbdis.2016.03.002 – volume: 38 start-page: 4309 year: 2020 end-page: 4315 ident: B17 article-title: Characterization of neutralizing monoclonal antibody against tick-borne encephalitis virus in vivo publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2020.04.051 – volume: 8 start-page: 1481 year: 2018 end-page: 1493 ident: B18 article-title: Current strategies for brain drug delivery publication-title: Theranostics doi: 10.7150/thno.21254 – volume: 296 start-page: 59 year: 2006 end-page: 62 ident: B15 article-title: Specific clinical and epidemiological features of tick-borne encephalitis in Western Siberia publication-title: Int J Med Microbiol doi: 10.1016/j.ijmm.2006.01.023 – volume: 64 start-page: 506 year: 2005 end-page: 512 ident: B57 article-title: Visualization of Central European tick-borne encephalitis infection in fatal human cases publication-title: J Neuropathol Exp Neurol doi: 10.1093/jnen/64.6.506 – volume: 55 start-page: 613 year: 2015 end-page: 631 ident: B20 article-title: Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev-pharmtox-010814-124852 – volume: 20 start-page: 107 year: 2015 end-page: 126 ident: B29 article-title: TEER measurement techniques for in vitro barrier model systems publication-title: J Lab Autom doi: 10.1177/2211068214561025 – volume: 57 start-page: 129 year: 2003 end-page: 146 ident: B11 article-title: Tick-borne encephalitis publication-title: Antiviral Res doi: 10.1016/s0166-3542(02)00206-1 – volume: 90 start-page: 1781 year: 2009 end-page: 1794 ident: B13 article-title: Tick-borne encephalitis virus - a review of an emerging zoonosis publication-title: J Gen Virol doi: 10.1099/vir.0.011437-0 – volume: 448 start-page: 39 year: 2007 end-page: 43 ident: B23 article-title: Transvascular delivery of small interfering RNA to the central nervous system publication-title: Nature doi: 10.1038/nature05901 – volume: 93 start-page: 94 year: 2012 end-page: 100 ident: B64 article-title: RNA interference inhibits replication of tick-borne encephalitis virus in vitro publication-title: Antiviral Res doi: 10.1016/j.antiviral.2011.10.023 – volume: 30 year: 2023 ident: B28 article-title: Development of an apolipoprotein E mimetic peptide-lipid conjugate for efficient brain delivery of liposomes publication-title: Drug Deliv doi: 10.1080/10717544.2023.2173333 – volume: 17 year: 2020 ident: B8 article-title: The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection publication-title: J Neuroinflammation doi: 10.1186/s12974-020-01943-w – volume: 122 start-page: 2067 year: 1999 end-page: 2078 ident: B12 article-title: The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994–98: a prospective study of 656 patients publication-title: Brain (Bacau) doi: 10.1093/brain/122.11.2067 – volume: 23 start-page: 549 year: 2018 end-page: 556 ident: B58 article-title: Small interfering RNA-mediated control of virus replication in the CNS is therapeutic and enables natural immunity to West Nile virus publication-title: Cell Host Microbe doi: 10.1016/j.chom.2018.03.001 – volume: 162 start-page: 239 year: 2012 end-page: 243 ident: B4 article-title: Tick-borne encephalitis: clinical findings and prognosis in adults publication-title: Wien Med Wochenschr doi: 10.1007/s10354-012-0105-0 – volume: 23 start-page: 24 year: 2016 end-page: 32 ident: B37 article-title: A VL-linker-VH orientation dependent single chain variable antibody fragment against rabies virus G protein with enhanced neutralizing potency in vivo publication-title: Protein Pept Lett doi: 10.2174/0929866522666151026122752 – volume: 543 start-page: 179 year: 2018 end-page: 189 ident: B44 article-title: RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2018.03.028 – volume: 45 start-page: 942 year: 1999 end-page: 956 ident: B49 article-title: Human anti-animal antibody interferences in immunological assays publication-title: Clin Chem doi: 10.1093/clinchem/45.7.942 – volume: 12 year: 2022 ident: B63 article-title: Progressive course of chronic tick-borne encephalitis manifesting as amyotrophic lateral sclerosis-like syndrome 35 years after the acute disease publication-title: Brain Sci doi: 10.3390/brainsci12081020 – volume: 224 year: 2019 ident: B40 article-title: Nanomaterial-based blood-brain-barrier (BBB) crossing strategies publication-title: Biomaterials doi: 10.1016/j.biomaterials.2019.119491 – volume: 85 start-page: 1007 year: 2004 end-page: 1018 ident: B24 article-title: Amino acid changes responsible for attenuation of virus neurovirulence in an infectious cDNA clone of the Oshima strain of tick-borne encephalitis virus publication-title: J Gen Virol doi: 10.1099/vir.0.19668-0 – volume: 218 year: 2021 ident: B27 article-title: Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease publication-title: J Exp Med doi: 10.1084/jem.20210236 – volume: 25 start-page: 7559 year: 2007 end-page: 7567 ident: B3 article-title: Field effectiveness of vaccination against tick-borne encephalitis publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2007.08.024 – volume: 30 start-page: 4195 year: 2009 end-page: 4202 ident: B45 article-title: Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles publication-title: Biomaterials doi: 10.1016/j.biomaterials.2009.02.051 – volume: 390 start-page: 139 year: 2009 end-page: 150 ident: B56 article-title: Mortality following peripheral infection with Tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses publication-title: Virology (Auckl) doi: 10.1016/j.virol.2009.04.026 – volume: 321 start-page: 198914 year: 2022 ident: B7 article-title: Necroptosis of neuronal cells is related to the neuropathology of tick-borne encephalitis publication-title: Virus Res doi: 10.1016/j.virusres.2022.198914 – volume: 8 start-page: 223 year: 2010 end-page: 232 ident: B5 article-title: Tick-borne encephalitis: pathogenesis and clinical implications publication-title: Travel Med Infect Dis doi: 10.1016/j.tmaid.2010.06.004 – volume: 32 start-page: 3589 year: 2014 end-page: 3594 ident: B16 article-title: A protective chimeric antibody to tick-borne encephalitis virus publication-title: Vaccine (Auckl) doi: 10.1016/j.vaccine.2014.05.012 – volume: 21 start-page: S11 year: 2003 end-page: S18 ident: B14 article-title: Tick-borne encephalitis—pathogenesis, clinical course and long-term follow-up publication-title: Vaccine (Auckl) doi: 10.1016/S0264-410X(02)00811-3 – volume: 12 start-page: 4117 year: 2015 end-page: 4122 ident: B38 article-title: Investigation of the structure of anti-human seminal plasma protein single-chain antibody and its association with linker peptide length publication-title: Mol Med Rep doi: 10.3892/mmr.2015.3980 – volume: 15 start-page: 1331 year: 2017 end-page: 1339 ident: B36 article-title: Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device publication-title: Plant Biotechnol J doi: 10.1111/pbi.12719 – volume: 16 year: 2019 ident: B33 article-title: Changes in cytokine and chemokine profiles in mouse serum and brain, and in human neural cells, upon tick-borne encephalitis virus infection publication-title: J Neuroinflammation doi: 10.1186/s12974-019-1596-z – volume: 45 start-page: 4690 year: 2016 end-page: 4707 ident: B21 article-title: Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery publication-title: Chem Soc Rev doi: 10.1039/c6cs00076b – volume: 388 start-page: 1631 year: 2023 end-page: 1632 ident: B52 article-title: Lecanemab in early Alzheimer's disease. Reply publication-title: N Engl J Med doi: 10.1056/NEJMc2301380 – volume: 179 start-page: 2577 year: 2022 end-page: 2588 ident: B48 article-title: Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: impact on medication efficacy and safety publication-title: Br J Pharmacol doi: 10.1111/bph.15802 – volume: 233 start-page: 167 year: 2000 end-page: 177 ident: B26 article-title: Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3’ to 5’ exonuclease activity publication-title: J Immunol Methods doi: 10.1016/s0022-1759(99)00184-2 – volume: 111 start-page: 161 year: 2005 end-page: 174 ident: B55 article-title: Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis publication-title: Virus Res doi: 10.1016/j.virusres.2005.04.007 – volume: 38 start-page: 141 year: 1994 end-page: 149 ident: B25 article-title: Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo publication-title: Acta Virol – volume: 17 start-page: 1532 year: 1999 end-page: 1539 ident: B60 article-title: Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization publication-title: Vaccine (Auckl) doi: 10.1016/S0264-410X(98)00360-0 – volume: 234 start-page: 16724 year: 2019 end-page: 16738 ident: B66 article-title: Antibody-drug therapeutic conjugates: potential of antibody-siRNAs in cancer therapy publication-title: J Cell Physiol doi: 10.1002/jcp.28490 – volume: 330 start-page: 512 year: 2023 end-page: 527 ident: B51 article-title: Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2023.13239 – volume: 1734 start-page: 146738 year: 2020 ident: B43 article-title: Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes publication-title: Brain Res doi: 10.1016/j.brainres.2020.146738 – volume: 37 year: 2020 ident: B41 article-title: RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer's disease publication-title: Pharm Res doi: 10.1007/s11095-020-02865-1 – volume: 58 start-page: 640 year: 2006 end-page: 656 ident: B50 article-title: Engineering of therapeutic antibodies to minimize immunogenicity and optimize function publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2006.01.026 – volume: 219 start-page: 357 year: 1996 end-page: 366 ident: B9 article-title: Importance of localized skin infection in tick-borne encephalitis virus transmission publication-title: Virology (Auckl) doi: 10.1006/viro.1996.0261 – volume: 64 start-page: 640 year: 2012 end-page: 665 ident: B19 article-title: Modern methods for delivery of drugs across the blood-brain barrier publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2011.11.010 – volume: 29 start-page: 175 year: 2013 end-page: 186 ident: B54 article-title: Antibody humanization methods - a review and update publication-title: Biotechnol Genet Eng Rev doi: 10.1080/02648725.2013.801235 |
| SSID | ssj0001626676 |
| Score | 2.2967703 |
| Snippet | Tick-borne encephalitis virus is a neuroinvasive pathogen that causes severe neurologic disease, significantly affecting patients' quality of life. No specific... Tick-borne encephalitis virus (TBEV) belongs to the genus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms... Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological... ABSTRACTTick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe... Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological... ABSTRACT Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0018425 |
| SubjectTerms | Animals Antibodies Antibodies, Neutralizing - administration & dosage Antibodies, Neutralizing - immunology Antibodies, Viral - administration & dosage Antibodies, Viral - genetics Antibodies, Viral - immunology Antiviral agents Arachnids Blood-brain barrier Blood-Brain Barrier - immunology Blood-Brain Barrier - virology Brain - virology C-Terminus Cell Line Central nervous system Drug delivery Drug delivery systems Encephalitis Encephalitis Viruses, Tick-Borne - immunology Encephalitis, Tick-Borne - therapy Encephalitis, Tick-Borne - virology Endothelial cells Endothelial Cells - virology Female Glycoproteins Humans Invasiveness Ligands Light Membrane permeability Mice Mice, Inbred BALB C Neurological diseases Peptide Fragments Plasmids Polypeptides Quality of life Rabies rabies virus glycoprotein recombinant antibody Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Research Article Tick-borne encephalitis tick-borne encephalitis virus Viral Proteins - genetics Viral Proteins - immunology Virology Viruses |
| SummonAdditionalLinks | – databaseName: American Society for Microbiology Open Access dbid: AAUOK link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_nHYIv4rerp0QQwYfobr6aPq7icSjqiwv3VpJ04i1y3WW7FfSvdybt9m7lEF-baRLmI_lNJplh7KXSKZYxUUGTFIWWAKJ0xomobGlU7XUd6IHz5y_2dKE_npmzA2Z2b2EGDrZvfHuRA_mjZUv39qKlp_ZA0QOnhTQ32JGRpUZ7PJrPF18_XR6uIEy3xRiWvOZXXIFxBLm3G-Wk_dchzb8vTF7ZgU7usNsDdOTzXtZ32QE099jNvpjkr_usu3L_h68S76-kByoBwYPfUGU6scaVLefJbb5zZOkyrOgSIUfgyhvo8qHHb2rDEX4I1I4GOFn--pzQ-rLlP5ebruXYIcJGnrt-wBYnH769PxVDUQXhjXRbAVMd0MsCmUxtfVE4lIcL02h1bZMutIFCp1DUYAOClaATeGtKDTVCQwVuqh6yw2bVwGPG65mE6GJEegRV3rhYqBnoELU1hfJmwl4Rj6udTKvscEhXDcKosjAqiYSvd1Ko1n2SjX_QviMxjXSUHjt_QGWpBmurkgL0-3APMBDJQXY-QooBZK29itJP2PFOyJezU5Je1aJ7i2O8GJvR2iiE4htYdUQjcUGmJIUT9qjXiXEmCI2knCk7YW5PW_amut_SLM9zRu8ZOYI48JP_5dhTdktSIeJ8znzMDrebDp4hOtqG54Mt_AF2OBF2 priority: 102 providerName: American Society for Microbiology – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA-6Ivgifl_1lAgi-BBuN1_NPomKxyHokwf7VpJ0crfItet2K-hf70za3b0VuddmaENnMvnNZDI_xt4oneI8JiI0SVFoCSDmzjgRlZ0bVXtdB7rg_PWbPTvXXxZmMSbcurGscusTs6Ou20g58hMl6c4jBh_m_eqnINYoOl0dKTRuszvUuoysulyU-xwLonVb7k4npTu56uiyPtD5g9OC-LEnvruSB5tS7t3_P8D5b93ktY3o9AG7PyJI_mFQ-UN2C5pH7O7AKfn7MeuvlQHxNvGhMj0QEwQPfk0EdWKFDi63y20uOP7ZZWiplpAjfuUN9Dn38YfG8As_BBpJA5wcwOqSQPuy47-W677j-EJEjzy_-gk7P_38_dOZGLkVhDfSbQRMdcBgC2QytfVl6VAtLkyj1bVNutQGSp1CWYMNiFmCTuCtmWuoESEqcFP1lE2atoEjxuuZhOhiRHnEVt64WKoZ6BC1NaXypmBv6R9X4-Loqhx3SFeNyqiyMiqJgu-2WqhWQ6-NG2Q_kpp2ctQlOz9o1xfVuOiqpADDP9wKDESKk52PkGIAWWuvovQFO94qeT-7vaEV7PVuGBcdnaT4BtqeZCT6ZepVWLBng03sZoIIScqZsgVzB9ZyMNXDkWZ5mRt7zygexA8_v3leL9g9SSzEOcl8zCabdQ8vERptwqts_38B5zgShQ priority: 102 providerName: ProQuest |
| Title | Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40622136 https://journals.asm.org/doi/10.1128/msphere.00184-25 https://www.proquest.com/docview/3234797175 https://www.proquest.com/docview/3227638679 https://pubmed.ncbi.nlm.nih.gov/PMC12306175 https://doaj.org/article/f3e9564675ec40208acefcbe2d4a3c2a |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dixMxEA9aEXwRv-15lggi-LBcm-8-9uSOQ_EUsdC3JclOvHLctrTdA_3rncnu1VZEX3xa2AzJbGZm85tkMsPYa6lSHMdEBU1SLJQAKMZOuyJKM9ay8qoKdMH547k5m6r3Mz3bKfVFMWFteuB24o6SBITwaM4aIvk6zkdIMYColJdRZGiEa96OM5V3VxCnG7s9lxTu6GpN1_SBTh6cKqgyds-vr8TecpSz9v8Jav4eMbmzBJ0-YPc77MgnLc8P2S2oH7G7bTXJ749ZsxMAxBeJtzHpgWpA8OBXVJquWOKvLSfKrb9xnNN5WFAUIUfkymto8q7HD2rDES4LVI8aOJn-8oLg-nzNr-erZs2xQ8SNPHf9hE1PT76-Oyu6qgqF18JtChiqgG4WiKQr4611KBAXhtGoyiRllQarUrAVmIBoJagE3uixggqxoQQ3lE9Zr17U8JzxaiQguhiRHlGV1y5aOQIVojLaSq_77A3NcdmZxbrMHodwZSeMMgujFEj49kYK5bLNsvEX2mMS05aO8mPnF6g1Zac15b-0ps8Ob4T8izsp6Fot-rc4xqttM5obnaH4GhYN0Qj8I1OWwj571urElhPERkKMpOkzt6cte6zut9Tzi5zSe0SeIA588D8-7gW7J6hKcd6EPmS9zaqBlwidNmHAbtuZHbA7k8n00wd8Hp-cf_4yyLbzE2NpIDQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKIgQXxJuUAkYCJA5Rd_1IvAeEeFVb-ji10t6C7UzaFWqy3WxA5UfxG5lxsrtdhHrrNR7Zo8yMZz57PMPYa6kKP_QFNTQpfKwEQDw02sReJkMtc6tyRw-cDw6T0bH6NtbjDfZn8RaG0ioXe2LYqPPK0xn5thT05hHBh_4wPY-paxTdri5aaLRqsQcXvxCy1e93v6B83wix8_Xo8yjuugrEVgszj6GvHMIMEIXOE5umBhkyru8TlSeFSpWGVBUuzSFx6K2dKsAmeqggx9hIgulLnPcGu4mOt09gLx2nqzMdRAdJurwNFWb7rKbiAED3HUbF1I-7Z-szseYEQ6-A_wW4_-ZpXnJ8O_fY3S5i5R9bFbvPNqB8wG61PSwvHrLmUtoRrwreZsI76jzBnZ1RQ7x4ihtqKM9bnnCU5MRVlLvIMV7mJTThrOU3jeEKP2JUyhI4bTjTUwIJk5r_nMyamuOEGK3yMPUjdnwtf_0x65VVCU8ZzwcCvPEe6TGWs9r4VA5AOa8SnUqrI_aW_nHWGWOdBZwjTNYJIwvCyAQSvltIIZu2tT2uoP1EYlrSUVXu8KGanWSdkWeFBISb6Ho0eMLlxnoovAORKyu9sBHbWgh5xd1KsSP2ajmMRk43N7aEqiEagX6AaiNG7EmrE0tOMCITYiCTiJk1bVljdX2knJyGQuIDwp-48ObVfL1kt0dHB_vZ_u7h3jN2R1AH5HDAvcV681kDzzEsm7sXwRY4-37dxvcXnKFPtA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJxAviG8CA4wESDxEbf2RuA8IMbZqY1BNiEl7C7Zz3iq0pDQtaPxp_HXcJWm7IrS3vcYn-5S7893Z5_sx9lKq4Ac-EKBJ8LESAPHAaBN7mQy0zK3KHT1w_jxK9o7Ux2N9vMH-LN7CUFnlYk-sN-q89HRG3pWC3jxi8qG7oS2LONwZvpv8iAlBim5aF3AajYocwPkvTN-qt_s7KOtXQgx3v37Yi1uEgdhqYWYx9JTDlANE0Hli09Qgc8b1fKLyJKhUaUhVcGkOiUPP7VQAm-iBghzjJAmmJ3Hea2wzpayowza3d0eHX1YnPJgrJOnyblSY7llFrQKAbj-Migmdu2OrM7HmEmvkgP-Fu_9WbV5wg8Pb7FYbv_L3jcLdYRtQ3GXXG0TL83tsfqEIiZeBN3XxjnAouLNTgseLJ7i91s16ixOOch27kioZOUbPvIB5ffLym8Zwhe8xqmgBnLafySmlDOOK_xxP5xXHCTF25fXU99nRlfz3B6xTlAU8YjzvC_DGe6THyM5q41PZB-W8SnQqrY7Ya_rHWWuaVVZnPcJkrTCyWhiZQMI3Cylkk6bTxyW02ySmJR316K4_lNOTrDX5LEjA5BMdkQZPWbqxHoJ3IHJlpRc2YlsLIa-4W6l5xF4sh9Hk6R7HFlDOiUagV6BOiRF72OjEkhOMz4ToyyRiZk1b1lhdHynGp3Vb8T5lo7jw48v5es5uoOFln_ZHB0_YTUFwyPVp9xbrzKZzeIox2sw9a42Bs29XbX9_AaapVU8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+blood-brain+barrier-penetrating+antibodies+for+neutralizing+tick-borne+encephalitis+virus+in+the+brain&rft.jtitle=mSphere&rft.au=Fukuta%2C+Mizuki&rft.au=Fukano%2C+Sayo&rft.au=Maekawa%2C+Naoya&rft.au=Kobayashi%2C+Shintaro&rft.date=2025-07-07&rft.issn=2379-5042&rft.eissn=2379-5042&rft.volume=10&rft.issue=7&rft_id=info:doi/10.1128%2Fmsphere.00184-25&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_msphere_00184_25 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5042&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5042&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5042&client=summon |